Serina Therapeutics, Inc. (SER)

Market Cap	19.52M -55.8%
Revenue (ttm)	116,000 -96.3%
Net Income	-18.80M
EPS	-1.92
Shares Out	10.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251,790
Open	2.090
Previous Close	2.100
Day's Range	1.760 - 2.230
52-Week Range	1.710 - 7.920
Beta	n/a
Analysts	Strong Buy
Price Target	13.00 (+618.23%)
Earnings Date	Mar 23, 2026

About SER

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In additio...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2018
• Employees: 13
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: SER
• Website: https://serinatherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for SER stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 618.23% from the latest price.

Price Target

$13.0

(618.23% upside)

Analyst Consensus: Strong Buy